Although blinatumomab can eradicate tumors at low effector-to-target (E:T) cell ratios through serial lysis [7, 19, 20], greater percentages of CD3+ T cell with correspondingly lower percentages of CD19+ B cells (i.e., lower tumor burden) create the optimal tumor-killing environment [8]. The gene discussed is CD19; the disease is neoplasm.